Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase II Study of OSI-774 (Tarceva) in Elderly Subjects With Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Authors not listed

Dana-Farber Cancer Institute · 2003

Dysbiosis Human Randomized controlled trial

Abstract

The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-25 MST

Cite this

APA

Anonymous. (2003). A Phase II Study of OSI-774 (Tarceva) in Elderly Subjects With Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC). <em>Dana-Farber Cancer Institute</em>. https://clinicaltrials.gov/study/NCT00137800

Vancouver

Anonymous. A Phase II Study of OSI-774 (Tarceva) in Elderly Subjects With Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC). Dana-Farber Cancer Institute. 2003.

BibTeX

@misc{anon2003APhase, title = {A Phase II Study of OSI-774 (Tarceva) in Elderly Subjects With Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)}, author = {Anonymous}, journal = {Dana-Farber Cancer Institute}, year = {2003}, }